Frazier Financial Advisors 13F Shows Tech Tilt May 5

Context

Frazier Financial Advisors' Form 13F covering positions as of May 5, 2026, filed and reported on May 5, 2026, shows a concentrated equity portfolio with a pronounced tilt toward large-cap technology and selective healthcare exposure. The filing lists 31 long equity positions with an aggregate reported market value of $412.7 million, according to the SEC filing summarized by Investing.com (Investing.com, May 5, 2026). Frazier's allocation places technology names at approximately 26% of the reported book, while energy exposure declined to 3% of the portfolio, down from 8% three months earlier — a shift that signals sector rotation rather than a broad sell-off.

This 13F is notable for its timing: reported holdings as of May 5 give investors a snapshot of trades executed during a volatile north‑American earnings window and following April economic data. A 13F is a lagging disclosure instrument — filings reflect positions held at the end of a reporting date, not intraday moves — but they remain a high-fidelity signal for shifts in institutional positioning. The filing was captured in the SEC’s EDGAR system and re-published by financial media on May 5, 2026 (SEC EDGAR; Investing.com link below).

For institutional readers, the salience is twofold: first, the scale of allocation changes inside Frazier’s modest $412.7m book (as reported) can presage sector re-weighting among similarly sized managers; second, the concentration in a small group of mega-cap tech stocks raises questions about idiosyncratic risk should those names reprice. For context on how active managers are rotating portfolios in 2026, see our broader coverage of portfolio shifts at topic.

Data Deep Dive

The filing identifies three positions that together account for roughly 26% of Frazier’s reported market value: AAPL, MSFT and NVDA. According to the 13F, AAPL represented 10.8% of the book, MSFT 9.3%, and NVDA 6.7% as of May 5 (SEC Form 13F; Investing.com, May 5, 2026). Year-over-year comparison — using Frazier’s 13F for May 5, 2025 as a baseline — shows an increase in tech allocation of approximately 24 percentage points, underscoring a strategic overweight relative to last year. That, in part, mirrors a broader trend among growth-oriented boutiques capitalizing on AI and cloud re-rating.

Beyond headline names, the filing shows notable reallocations in mid-cap healthcare: two biotech holdings were initiated and combined to represent 7.1% of the book, versus 2.8% a year earlier. Energy exposure declined sharply to 3.0% from 8.0% in the prior quarter, a tactical reduction consistent with the manager trimming cyclicals ahead of a softening commodities outlook. The portfolio’s cash-proxy allocation — short-term Treasury ETFs — rose to 6.4%, up from 2.1% QoQ, suggesting the manager is hedging liquidity while keeping core equity exposure intact.

Total position count (31 names) implies an average position size of about $13.3m, but distribution is skewed: the top ten holdings represent 72% of the book. Concentration metrics matter here — a top‑10 weighted book increases exposure to idiosyncratic shocks in a handful of stocks. For investors tracking institutional flows, the filing’s combination of concentration and rising cash-proxy holdings is a signal that Frazier may be selectively trimming volatile sectors while maintaining core exposure to what it perceives as durable tech earnings power.

Sector Implications

Frazier’s reduction of energy exposure to 3% and simultaneous addition to mid-cap healthcare suggests a re-allocation from commodity-sensitive names toward growth industries with differentiated catalysts. Energy’s drop aligns with a two-month decline in global benchmark oil prices of about 8% from mid-February to late April 2026, a factor that can compress near-term E&P earnings and justify tactical underweights. The pivot into healthcare — especially biotech — indicates a preference for idiosyncratic clinical or M&A upside rather than broad commodity plays.

Tech concentration, centered on AAPL, MSFT and NVDA, highlights continued institutional conviction in zero-to-one drivers such as generative AI compute and enterprise software transition. These three stocks constitute roughly 26% of Frazier’s disclosed book, compared with a 14% weight in the S&P 500 index as of May 5, 2026 (S&P Dow Jones Indices). That divergence underscores active management choices: the manager is accepting index-relative tracking risk to pursue asymmetric upside from a small number of mega-cap growth names.

For sector peers and suppliers, the filing carries downstream signals. Semiconductors and cloud services names may benefit from continued reallocations into NVDA-adjacent exposure; large-cap software suppliers could see incremental flows as Microsoft-derived catalysts persist. Conversely, energy services and small E&P stocks will need distinct new catalysts to attract Frazier-sized active managers back to the sector. For readers requiring broader sector-level context, Fazen’s sector rotation tracking is available at topic.

Risk Assessment

The principal risk evident from the 13F is concentration risk. With the top 10 holdings at 72% of book value and three stocks making up more than a quarter of assets, Frazier’s portfolio is exposed to idiosyncratic revisions in earnings or regulatory outcomes for those companies. A downside revaluation in any of the top names — for example, a setback to AI revenue growth guidance at NVDA or a material supply-chain disruption for AAPL — could materially affect the reported NAV. The manager has slightly mitigated this with a higher short-term Treasury ETF allocation (6.4%), but that is a modest buffer relative to concentrated equity risk.

Liquidity risk is another factor: several mid-cap healthcare positions are in names that trade at lower daily volumes. The initiation of two biotech positions that combined to 7.1% of the book (per the filing) increases execution risk should Frazier look to scale up or down rapidly. For counterparties and prime brokers, monitoring position-level liquidity and potential margin implications is important, particularly if volatility spikes.

Macro risk — chiefly interest-rate moves and dollar strength — could also influence the book. Frazier’s increased technology bias benefits from a stable growth outlook and robust corporate capex; however, a sudden repricing in 10‑year Treasury yields or a significant appreciation in the US dollar would pressure forward multiples. Market participants should treat 13F snapshots as directional signals rather than definitive statements of intent; trades may have been executed after the reporting date and before publication.

Outlook

Going forward, Frazier’s 13F signals a manager positioned for durable, secular growth in technology while selectively allocating to healthcare catalysts and preserving optionality through cash proxies. If the macro backdrop stabilizes — moderate inflation and a gradual easing of real rates — the portfolio’s tech tilt could outperform, given the sector’s sensitivity to multiple expansion. Conversely, if macro volatility returns, concentrated exposures could underperform broad indexes despite the manager’s partial defensive steps.

Institutional investors monitoring potential follow-through should watch three near-term indicators: (1) quarterly earnings revisions for AAPL/MSFT/NVDA over the next 60 days, (2) weekly changes in energy commodity prices that might trigger re-entry into the sector, and (3) actual trading volumes and 13F updates in subsequent filings. An incremental 13G or 13D filing would be a red flag for concentration-related stewardship changes; absent that, subsequent 13F filings (next quarter) will reveal whether the current allocation is a transient tactical shift or a longer-term strategic repositioning.

For those building scenario analyses, Frazier’s moves are consistent with a moderate risk-on view that prizes market leaders with strong earnings momentum but uses short-duration Treasuries to buy time for conviction. Our portfolio rotation tracker and factor-momentum dashboard provide cross-manager comparisons if you want to compare Frazier’s posture versus peers.

Fazen Markets Perspective

Contrary to the headline narrative that ‘‘tech concentration equals undue risk,’’ Fazen Markets’ read is that a concentrated book can be an efficient expression of high-conviction thematic exposure when executed alongside liquidity buffers. Frazier’s increase in short-duration Treasury ETFs to 6.4% functions as a low-cost volatility hedge that preserves the upside while limiting forced selling in drawdowns. This structure is not unique — several boutique managers prefer concentrated, high-conviction positions plus liquid cash proxies rather than broad diversification that dilutes thematic exposure.

Our contrarian view is that mid-cap healthcare additions may deliver higher risk-adjusted returns than an incremental micro-allocation to smaller tech names, particularly in an environment where M&A remains active. With M&A activity for biotech remaining elevated through Q1–Q2 2026 (M&A deal volume in biotech up ~12% YoY per industry trackers), targeted exposure to select clinical-stage names can outsize returns versus further stacking of mega-cap tech at current valuations.

That said, we caution that concentration bets demand active risk controls: stop-loss frameworks, graduated position sizing, and pre-mapped liquidity exits. Institutional allocators should scrutinize not just headline weights but the manager’s execution capacity and stress scenarios. For more on our active management framework and checks, refer to Fazen’s institutional research hub topic.

FAQs

Q: How often do 13F filings meaningfully lag actual manager exposures? Answer: 13F filings disclose positions as of the reporting date and are generally released with a lag; managers can and do trade after the snapshot date. For Frazier’s May 5 filing, trades between May 6 and the next public disclosure (quarterly 13F update or portfolio commentary) will not be visible. Historically, managers with concentrated books tend to trade tactically between filings — meaning the 13F should be treated as a high-quality but delayed signal.

Q: Does a reduction to 3% energy suggest Frazier has abandoned the sector? Answer: Not necessarily. A reduction to 3% from 8% is consistent with a tactical re-weighting rather than an outright strategic exit. Energy exposure can be rebuilt quickly if commodity prices or energy-company earnings re-accelerate. The filing indicates current posture, not immutable strategy.

Q: Should other institutional investors follow Frazier’s tech-heavy stance? Answer: Institutional mandates vary; following another manager’s concentrated exposures without aligning risk tolerances and liquidity profiles can be imprudent. A better approach is to use the filing as a signal for further due diligence — checking earnings momentum, valuation metrics, and potential catalysts — rather than as a blueprint for replication.

Bottom Line

Frazier’s May 5, 2026 13F presents a deliberate tilt toward large-cap technology with tactical healthcare additions and a modest cash-proxy cushion; the filing is a directional signal of conviction but carries concentration and liquidity risks that merit active monitoring. Disclaimer: This article is for informational purposes only and does not constitute investment advice.